Metadata
Author: Tico19
Data
English[en]
The interleukin-6 receptor antagonist was approved by the FDA based on retrospective case studies for treatment of steroid refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.
Chinese[zh]
2017 年,在回顾性病例研究的支持下,FDA 批准使用白细胞介素 6 受体拮抗剂治疗由其他原因引起的类固醇难治性细胞因子释放综合征,即 CAR T 细胞疗法。